statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

StockNews.com began coverage on shares of Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) in a research note issued on Sunday. The brokerage set a "hold" rating on the biopharmaceutical...

StockNews.com Initiates Coverage on Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics Inc. (NASDAQ:RGLS  Get Free Report) saw a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 5,130,000...

Short Interest in Regulus Therapeutics Inc. (NASDAQ:RGLS) Grows By 9,244.3%

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS  Get Free Report) have been given a consensus rating of Moderate Buy by the five brokerages that are currently covering the...

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $7.50 Average Target Price from Analysts

Equities research analysts at StockNews.com began coverage on shares of Regulus Therapeutics (NASDAQ:RGLS  Get Free Report) in a report released on Saturday. The brokerage set a...

Financial and Clinical Progress Amidst Net Loss Wider Than EstimatesRelated Stocks: RGLS...

Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
RGLS stock results show that Regulus Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
The post...

RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023

HC Wainwright reaffirmed their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS  Free Report) in a research report report published on Monday, Benzinga reports. They currently have a...

HC Wainwright Reaffirms "Buy" Rating for Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics Inc. (NASDAQ:RGLS  Free Report)  Equities researchers at Leerink Partnrs issued their FY2025 earnings per share estimates for Regulus Therapeutics in a research...

Analysts Issue Forecasts for Regulus Therapeutics Inc.'s FY2025 Earnings (NASDAQ:RGLS)

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates...

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.

Volume	204,765.00
52-Wk High	$3.79
52-Wk Low	$1.08

RGLS Regulus Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals